Mavacamten in Real-Life Practice: Initial Experience at a Hypertrophic Cardiomyopathy Centre
Our real-world experience aligns with established mavacamten trial outcomes. Continuous vigilance and longitudinal investigations are needed to further assess potential long-term impacts.
Authors
- M. Fuad Jan (ORCID: https://orcid.org/0000-0001-5072-710X)
- Muddasir Ashraf (ORCID: https://orcid.org/0000-0001-9710-7610)
- Stacie Kroboth (ORCID: https://orcid.org/0000-0001-8767-4021)
- Arshad Jahangir (ORCID: https://orcid.org/0000-0002-0221-8017)
- A. Jamil Tajik (ORCID: https://orcid.org/0000-0002-4784-1275)
- Patrycja Galazka (ORCID: https://orcid.org/0000-0002-5952-7996)
- Zaid Abood (ORCID: https://orcid.org/0009-0005-8164-9024)
- Heather Sanders
- Emily Ollerman
- McKenzie Schweitzer
- Amanda Misicka
Institutions
- Aurora Health Care (US)
- University School of Milwaukee (US)
- Aurora St. Luke's Medical Center (US)
- Milwaukee Health Department (US)
- University of Wisconsin–Milwaukee (US)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1002/ehf2.14882
- Citations
- 11
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.42